Murphy, Middleton, Hinkle & Parker, Inc. Bristol Myers Squibb CO Transaction History
Murphy, Middleton, Hinkle & Parker, Inc.
- $185 Million
- Q3 2024
A detailed history of Murphy, Middleton, Hinkle & Parker, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Murphy, Middleton, Hinkle & Parker, Inc. holds 8,145 shares of BMY stock, worth $450,255. This represents 0.23% of its overall portfolio holdings.
Number of Shares
8,145
Previous 8,478
3.93%
Holding current value
$450,255
Previous $352,000
19.6%
% of portfolio
0.23%
Previous 0.2%
Shares
12 transactions
Others Institutions Holding BMY
# of Institutions
2,457Shares Held
1.5BCall Options Held
29.6MPut Options Held
32.1M-
Vanguard Group Inc Valley Forge, PA187MShares$10.3 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$8.77 Billion0.15% of portfolio
-
State Street Corp Boston, MA91.4MShares$5.06 Billion0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY74.6MShares$4.13 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA59.1MShares$3.26 Billion0.47% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $118B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...